The ecology of brain tumors: Lessons learned from neurofibromatosis-1

Oncogene

Volumn 30, Issue 10, 2011, Pages 1135-1146

  Pong, W W ^a   Gutmann, D H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

astrocytoma; glioma; microenvironment; neurofibromatosis type 1; NF1; stroma

Indexed keywords

CARCINOGENESIS; CELL TYPE; GENETIC HETEROGENEITY; GLIOMA; HUMAN; INTRACELLULAR SPACE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANIMALS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR MATRIX; HUMANS; MICE; NEUROFIBROMATOSIS 1; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 79952537382     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.519     Document Type: Review

References (123)

1. Alcantara Llaguno S, Chen J, Kwon C, Jackson EL, Li Y, Burns DK et al. (2009). Malignant astrocytomas originate from neural stem/ progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15: 45-56.
2. Amankulor NM, Hambardzumyan D, Pyonteck SM, Becher OJ, Joyce JA, Holland EC. (2009). Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J Neurosci 29: 10299-10308.
3. Badie B, Schartner J, Klaver J, Vorpahl J. (1999). In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Neurosurgery 44: 1077-1082; discussion 1082-3.
4. Bajenaru ML, Garbow JR, Perry A, Hernandez MR, Gutmann DH. (2005). Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. Ann Neurol 57: 119-127. (Pubitemid 40053323)
5. Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR et al. (2003). Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63: 8573-8577. (Pubitemid 38064027)
6. Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. (2002). Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol 22: 5100-5113. (Pubitemid 34700701)
7. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221. (Pubitemid 19110302)
8. Ballester R, Marchuk D, Boguski M, Saulino AM, Letcher R, Wigler M et al. (1990). The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63: 851-859. (Pubitemid 120035058)
9. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. (1993). Cytotoxicity of microglia. Glia 7: 111-118.
10. Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG et al. (2010). The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 70: 1356-1366.
11. Barcellos-Hoff MH, Ravani SA. (2000). Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60: 1254-1260. (Pubitemid 30151992)
12. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. (1992). Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356: 713-715.
13. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S et al. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851. (Pubitemid 38174665)
14. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P et al. (1996). Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12: 144-148. (Pubitemid 26051293)
15. Brown JA, Gianino SM, Gutmann DH. (2010). Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibro-matosis-1 heterozygosity. J Neurosci 30: 5579-5589.
16. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82. (Pubitemid 46054518)
17. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL et al. (1983). Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305: 779-784. (Pubitemid 13010953)
18. Charles N, Ozawa T, Squatrito M, Bleau A, Brennan CW, Hambardzumyan D et al. (2010). Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6: 141-152.
19. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R et al. (2005). Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24: 5053-5068. (Pubitemid 41129083)
20. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382-1397. (Pubitemid 29270244)
21. Coussens LM, Tinkle CL, Hanahan D, Werb Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
22. Coussens LM, Werb Z. (2010). Inflammation and cancer. Nature 420: 860-867.
23. Dabbous MK, Walker R, Haney L, Carter LM, Nicolson GL, Woolley DE. (1986). Mast cells and matrix degradation at sites of tumour invasion in rat mammary adenocarcinoma. Br J Cancer 54: 459-465. (Pubitemid 16031549)
24. Daginakatte GC, Gianino SM, Zhao NW, Parsadanian AS, Gutmann DH. (2008). Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 68: 10358-10366.
25. Dasgupta B, Dugan LL, Gutmann DH. (2003). The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 23: 8949-8954. (Pubitemid 37210908)
26. Dasgupta B, Li W, Perry A, Gutmann DH. (2005a). Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 65: 236-245. (Pubitemid 40070815)
27. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. (2005b). Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 65: 2755-2760. (Pubitemid 40490077)
28. De Haas AH, Boddeke HW, Biber K. (2008). Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 56: 888-894.
29. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC et al. (1992). Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in Von Recklinghausen (type 1) neurofibromatosis. Cell 69: 265-273.
30. Dighe AS, Richards E, Old LJ, Schreiber RD. (1994). Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1: 447-456.
31. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299: 2423-2436. (Pubitemid 351749241)
32. Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. (2002). Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2: 507-514. (Pubitemid 41043955)
33. Dryja TP, Cavenee W, White R, Rapaport JM, Petersen R, Albert DM et al. (1984). Homozygosity of chromosome 13 in retinoblastoma. N Engl J Med 310: 550-553. (Pubitemid 14193093)
34. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998. (Pubitemid 35363648)
35. Egeblad M, Littlepage LE, Werb Z. (2005). The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 70: 383-388. (Pubitemid 44124893)
36. Ehrhardt A, David MD, Ehrhardt GR, Schrader JW. (2004). Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen. Mol Cell Biol 24: 6311-6323. (Pubitemid 38891132)
37. Elkabes S, DiCicco-Bloom EM, Black IB. (1996). Brain microglia/ macrophages express neurotrophins that selectively regulate micro-glial proliferation and function. J Neurosci 16: 2508-2521. (Pubitemid 26122673)
38. Fearon ER, Vogelstein B, 1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
39. Forstreuter F, Lucius R, Mentlein R. (2002). Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J Neuroimmunol 132: 93-98. (Pubitemid 35333330)
40. Gabbiani G, Chaponnier C, Huttner I. (1978). Cytoplasmic filaments and gap junctions in epithelial cells and myofibroblasts during wound healing. J Cell Biol 76: 561-568. (Pubitemid 8295898)
41. Gabbiani G, Hirschel BJ, Ryan GB, Statkov PR, Majno G. (1972). Granulation tissue as a contractile organ. A study of structure and function. J Exp Med 135: 719-734.
42. Giordano MJ, Mahadeo DK, He YY, Geist RT, Hsu C, Gutmann DH. (1996). Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia. J Neurosci Res 43: 246-253. (Pubitemid 26044238)
43. Graeber MB, Scheithauer BW, Kreutzberg GW. (2002). Microglia in brain tumors. Glia 40: 252-259. (Pubitemid 35337382)
44. Graves DT, Jiang YL, Williamson MJ, Valente AJ. (1989). Identification of monocyte chemotactic activity produced by malignant cells. Science 245: 1490-1493. (Pubitemid 19243238)
45. Green SR, Han KH, Chen Y, Almazan F, Charo IF, Miller YI et al. (2006). The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/ CX3CL1 via p38 MAPK. J Immunol 176: 7412-7420. (Pubitemid 43849043)
46. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE et al. (1997). The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278: 51-57. (Pubitemid 27274517)
47. Gutmann DH, Daginakatte GC. (2007). Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16: 1098-1112. (Pubitemid 47062730)
48. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. (1999). Creation of human tumour cells with defined genetic elements. Nature 400: 464-468. (Pubitemid 29361801)
49. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
50. Hart IR, Fidler IJ. (1980). Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 40: 2281-2287. (Pubitemid 10082239)
51. Hawes JJ, Tuskan RG, Reilly KM. (2007). Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. Neurogenetics 8: 121-130. (Pubitemid 46356250)
52. Hegedus B, Banerjee D, Yeh TH, Rothermich S, Perry A, Rubin JB et al. (2008). Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 68: 1520-1528. (Pubitemid 351346861)
53. Hegedus B, Hughes FW, Garbow JR, Gianino S, Banerjee D, Kim K et al. (2009). Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma. J Neuropathol Exp Neurol 68: 542-551.
54. Held-Feindt J, Hattermann K, Muerkoster SS, Wedderkopp H, Knerlich-Lukoschus F, Ungefroren H et al. (2010). CX3CR1 promotes recruitment of human glioma-infiltrating microglia/ macrophages (GIMs). Exp Cell Res 316: 1553-1566.
55. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC. (1997). Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17: 3217-3224. (Pubitemid 27522273)
56. Huettner C, Paulus W, Roggendorf W. (1995). Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146: 317-322.
57. Huson SM, Harper PS, Compston DA. (1988). Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111(Pt 6): 1355-1381. (Pubitemid 19028458)
58. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. (2005). The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102: 8573-8578. (Pubitemid 40862777)
59. Johansson G, Mahller YY, Collins MH, Kim M, Nobukuni T, Perentesis J et al. (2008). Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 7: 1237-1245.
60. Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M et al. (2008). Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68: 7342-7351.
61. Keski-Oja J, Raghow R, Sawdey M, Loskutoff DJ, Postlethwaite AE, Kang AH et al. (1988). Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem 263: 3111-3115. (Pubitemid 18072759)
62. Khalaf WF, Yang F, Chen S, White HA, Bessler W, Ingram DA et al. (2007). K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/- mast cells. J Immunol 178: 2527-2534. (Pubitemid 46233454)
63. Klein RS, Rubin JB. (2004). Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol 25: 306-314. (Pubitemid 38610354)
64. Knudson AG. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823.
65. Kunkel P, Muller S, Schirmacher P, Stavrou D, Fillbrandt R, Westphal M et al. (2001). Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro Oncol 3: 82-88. (Pubitemid 33691765)
66. Lee DY, Yeh TH, Emnett RJ, White CR, Gutmann DH. (2010). Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev 24: 2317-2329.
67. Lee YJ, Streuli CH. (1999). Extracellular matrix selectively modulates the response of mammary epithelial cells to different soluble signaling ligands. J Biol Chem 274: 22401-22408.
68. Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST. (1997). Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 93: 518-527. (Pubitemid 27186993)
69. Li F, Munchhof AM, White HA, Mead LE, Krier TR, Fenoglio A et al. (2006). Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum Mol Genet 15: 1921-1930. (Pubitemid 43821782)
70. Li H, Liu Y, Zhang Q, Jing Y, Chen S, Song Z et al. (2009). Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatr Res 65: 613-618.
71. Lin EY, Li J, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA et al. (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238-11246. (Pubitemid 46009952)
72. Listernick R, Charrow J, Greenwald M, Mets M. (1994). Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 125: 63-66. (Pubitemid 24225179)
73. Listernick R, Charrow J, Greenwald MJ, Esterly NB. (1989). Optic gliomas in children with neurofibromatosis type 1. J Pediatr 114: 788-792. (Pubitemid 19122974)
74. Listernick R, Darling C, Greenwald M, Strauss L, Charrow J. (1995). Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 127: 718-722.
75. Listernick R, Louis DN, Packer RJ, Gutmann DH. (1997). Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41: 143-149. (Pubitemid 27082094)
76. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007). WHO Classification of Tumours of the Central Nervous System. IARC Press: Lyon.
77. Ludwig HC, Feiz-Erfan I, Bockermann V, Behnke-Mursch J, Schallock K, Markakis E. (2000). Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas. Anticancer Res 20: 299-304. (Pubitemid 30189770)
78. Martinet N, Beck G, Bernard V, Plenat F, Vaillant P, Schooneman F et al. (1992). Mechanism for the recruitment of macrophages to cancer site. In vivo concentration gradient of monocyte chemotactic activity. Cancer 70: 854-860.
79. Marn-Teva JL, Dusart I, Colin C, Gervais A, Van Rooijen N, Mallat M, 2004, Microglia promote the death of developing Purkinje cells. Neuron, 41, 535-547. (Pubitemid 38253066)
80. McDaniel AS, Allen JD, Park S, Jaffer ZM, Michels EG, Burgin SJ et al. (2008). Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood 112: 4646-4654.
81. Morgan KJ, Rowley MA, Wiesner SM, Hasz DE, Van Ness B, Largaespada DA. (2007). The GAP-related domain of neurofibro-min attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells. Leuk Res 31: 1107-1113.
82. Munchhof AM, Li F, White HA, Mead LE, Krier TR, Fenoglio A et al. (2006). Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Hum Mol Genet 15: 1858-1869. (Pubitemid 43821776)
83. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011. (Pubitemid 29472907)
84. Pemov A, Park C, Reilly KM, Stewart DR. (2010). Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency. BMC Genomics 11: 194.
85. Pollard JW. (2008). Macrophages define the invasive microenviron-ment in breast cancer. J Leukoc Biol 84: 623-630.
86. Prendergast GC, Rane N. (2001). Farnesyltransferase inhibitors: mechanism and applications. Expert Opin Investig Drugs 10: 2105-2116. (Pubitemid 33150351)
87. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. (2000). Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26: 109-113.
88. Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT et al. (2004). Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci USA 101: 13008-13013. (Pubitemid 39167574)
89. Ren Y, Chan HM, Li Z, Lin C, Nicholls J, Chen CF et al. (2004). Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene 23: 4146-4154. (Pubitemid 38747946)
90. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. (1985). Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 82: 119-123. (Pubitemid 15168226)
91. Roumier A, Bechade C, Poncer J, Smalla K, Tomasello E, Vivier E et al. (2004). Impaired synaptic function in the microglial KARAP/ DAP12-deficient mouse. J Neurosci 24: 11421-11428. (Pubitemid 39658277)
92. Rozario T, DeSimone DW. (2010). The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol 341: 126-140.
93. Sandsmark DK, Zhang H, Hegedus B, Pelletier CL, Weber JD, Gutmann DH. (2007). Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res 67: 4790-4799. (Pubitemid 46910187)
94. Sasaki A, Ishiuchi S, Kanda T, Hasegawa M, Nakazato Y. (2001). Analysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell lines. Brain Tumor Pathol 18: 13-21.
95. Schor SL, Schor AM, Grey AM, Rushton G. (1988). Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J Cell Sci 90(Pt 3): 391-399.
96. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111. (Pubitemid 32391043)
97. Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD et al. (2007). Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 67: 890-900.
98. Singhal S, Birch JM, Kerr B, Lashford L, Evans DG. (2002). Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child 87: 65-70. (Pubitemid 34753778)
99. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS et al. (2001). Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61: 4956-4960. (Pubitemid 32681517)
100. Stern J, Jakobiec FA, Housepian EM. (1980). The architecture of optic nerve gliomas with and without neurofibromatosis. Arch Ophthal-mol 98: 505-511. (Pubitemid 10133653)
101. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW et al. (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98: 137-146. (Pubitemid 29344902)
102. Sun T, Gianino SM, Jackson E, Piwnica-Worms D, Gutmann DH, Rubin JB. (2010). CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. J Neuroimmunol 1: 1-6.
103. Suzuki M, Mose ES, Montel V, Tarin D. (2006). Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 169: 673-681. (Pubitemid 44156323)
104. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P et al. (2005). Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8: 323-335. (Pubitemid 41443417)
105. Thiagalingam S, Flaherty M, Billson F, North K. (2004). Neuro-fibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 111: 568-577. (Pubitemid 38293118)
106. Tong J, Hannan F, Zhu Y, Bernards A, Zhong Y. (2002). Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 5: 95-96. (Pubitemid 34121572)
107. Tremblay G. (1979). Stromal aspects of breast carcinoma. Exp Mol Pathol 31: 248-260. (Pubitemid 10222820)
108. Ueoka DI, Nogueira J, Campos JC, Maranhao Filho P, Ferman S, Lima MA. (2009). Brainstem gliomas-retrospective analysis of 86 patients. J Neurol Sci 281: 20-23.
109. Vousden KH. (2002). Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602: 47-59. (Pubitemid 34311899)
110. Wagner S, Czub S, Greif M, Vince GH, Suss N, Kerkau S et al. (1999). Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer 82: 12-16. (Pubitemid 29266099)
111. Walsh AB, Bar-Sagi D. (2001). Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 276: 15609-15615.
112. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM et al. (2009). Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 2393-2404.
113. Warrington NM, Gianino SM, Jackson E, Goldhoff P, Garbow JR, Piwnica-Worms D et al. (2010). Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofi-bromatosis-1. Cancer Res 70: 5717-5727.
114. Warrington NM, Woerner BM, Daginakatte GC, Dasgupta B, Perry A, Gutmann DH et al. (2007). Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res 67: 8588-8595. (Pubitemid 47437434)
115. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA et al. (2004). IL-6 is required for glioma development in a mouse model. Oncogene 23: 3308-3316. (Pubitemid 38669820)
116. Werb Z, Banda MJ, Jones PA. (1980). Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycopro-teins, and collagen by proteinases isolated from macrophages. J Exp Med 152: 1340-1357. (Pubitemid 11241633)
117. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D et al. (2006). Phase I trial and pharmacokinetic study of the farnesyl-transferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 24: 507-516. (Pubitemid 46630471)
118. Williams JA, Pontzer CH, Shacter E. (2000). Regulation of macro-phage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase. J Interferon Cytokine Res 20: 291-298. (Pubitemid 30169740)
119. Xu J, Ismat FA, Wang T, Yang J, Epstein JA. (2007). NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response. Circulation 116: 2148-2156. (Pubitemid 350060352)
120. Yan J, Chen S, Zhang Y, Li X, Li Y, Wu X et al. (2008). Rac1 mediates the osteoclast gains-in-function induced by haploinsuffi-ciency of Nf1. Hum Mol Genet 17: 936-948. (Pubitemid 351426028)
121. Yang F, Chen S, Robling AG, Yu X, Nebesio TD, Yan J et al. (2006). Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116: 2880-2891. (Pubitemid 44684473)
122. Yeh TH, Lee DY, Gianino SM, Gutmann DH. (2009). Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia 57: 1239-1249.
123. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C et al. (2005). Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 132: 5577-5588. (Pubitemid 43125883)